Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-Streptococcus mutans IgY
- Development stage
- Phase 3
- Lead developer
- Zhejiang University
- Modality
- Antibody-Based Therapeutics
- Administration
- Topical
01
Overview
Aoliding is a passive immunotherapy agent consisting of egg yolk antibodies (IgY) specifically targeting *Streptococcus mutans*, the primary causative agent of dental caries. Developed in collaboration with or studied by Zhejiang University, it is designed to prevent dental caries by inhibiting the adhesion and colonization of cariogenic bacteria on tooth surfaces. By binding to bacterial antigens such as glucosyltransferases (GTFs) and protein antigen c (PAc), the IgY antibodies disrupt biofilm formation and reduce the acidogenic potential of the oral microbiota. It is typically administered topically as a spray, rinse, or incorporated into dental products and is being evaluated in clinical trials for its efficacy in preschool children.
- Brand names
- Aoliding
- Other names
- Immunoglobulin Yolkanti-S. mutans IgYanti-caries IgYegg yolk antibodies
02
Targets
Gtf (Streptococcus mutans glucosyltransferase)AgI/II (Antigen I/II)
Beyond the preview
Go deeper on anti-Streptococcus mutans IgY.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-Streptococcus mutans IgY.